How much funding has Genesis Molecular AI raised?

Genesis Molecular AI has raised $200.0M in total funding, most recently a Series B round.

Who are Genesis Molecular AI's investors?

Genesis Molecular AI's investors include Andreessen Horowitz, T. Rowe Price, BlackRock, Fidelity Management.

When was Genesis Molecular AI founded?

Genesis Molecular AI was founded in 2019.

Where is Genesis Molecular AI headquartered?

Genesis Molecular AI is headquartered in Burlingame, California, United States.

What industry is Genesis Molecular AI in?

Genesis Molecular AI operates in Artificial Intelligence, Healthcare.

How many employees does Genesis Molecular AI have?

Genesis Molecular AI has 51-200 employees.

Genesis Molecular AI

Foundation models for drug discovery

Burlingame, United States · Founded 2019 · $200.0M raised

Artificial Intelligence

Healthcare

Headquarters: Burlingame, California
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: genesis.ml
Total Funding: $200.0M
Last Round: $200.0M Series BAug 2023
Rounds: 1

About

Genesis Molecular AI (formerly Genesis Therapeutics) is an AI-first drug discovery and development company headquartered in Burlingame, California. Founded in 2019, the company builds foundation models and an AI operating system — GEMS (Generative AI for Drug Discovery) — for small molecule drug design, integrating generative AI with physics-based modeling to identify potent, selective drug candidates against chemically complex targets at unprecedented speed. Its 3D diffusion foundation model Pearl achieves field-leading performance in drug-protein structure prediction. Genesis operates a fully integrated laboratory in San Diego and partners with major pharmaceutical companies to co-discover and co-develop medicines. The company raised a $200M Series B in 2023 and has partnerships with NVIDIA Healthcare and Incyte.

Summary

Genesis Molecular AI is an Artificial Intelligence company based in Burlingame, United States, founded in 2019. It has raised $200.0M in total across 1 round, most recently a $200.0M Series B round in Aug 2023. Investors include Andreessen Horowitz, T. Rowe Price and BlackRock.

LinkedIn GitHub